Home>Topics>>Myriad Genetics ([[MYGN]] -2.9%) shares slide after the U.S. Supreme Court agreed to hear a challenge to the practice of issuing patents on human genes. Goldman Sachs cuts shares to Neutral from Buy ...
Myriad Genetics ([[MYGN]] -2.9%) shares slide after the U.S. Supreme Court agreed to hear a challenge to the practice of issuing patents on human genes. Goldman Sachs cuts shares to Neutral from Buy ...
Myriad Genetics (
MYGN -2.9% ) shares slide after the U.S. Supreme Court agreed to hear a challenge to the practice of issuing patents on human genes.
Goldman Sachs cuts shares to Neutral from Buy on concerns that a final decision likely won't be reached before midyear. But
Jefferies maintains its ...
Read the rest of this article on SeekingAlpha.com: SA Currents